Bioavailability Study of Diclofenac 2.32% Gel in Healthy Adults

The primary objective of this study is to evaluate the **bioavailability** of Diclofenac 2.32% Gel in healthy adult subjects. This is clinically relevant as it assesses the extent and rate at which the active ingredient becomes available at the site of action, which is crucial for determining the efficacy and safety of the topical formulation. No secondary objectives are specified for this study.

The clinical trial involves a **study population** that includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants do not have any specific **medical conditions** as a prerequisite for inclusion in the trial. Information regarding lifestyle considerations such as diet, physical activity, or habits has not been provided. The selection criteria for the trial population, including any key inclusion or exclusion criteria, have not been detailed by the sponsor.

The clinical trial is designed to evaluate the **bioavailability** of Diclofenac 2.32% Gel in healthy adult subjects. This study is a Phase 2 trial, which is categorized as a comparative bioavailability study. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated recruitment start date is November 12, 2023, with an anticipated end date of March 21, 2024, indicating an overall trial duration of approximately four months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. The sequence of study visits will include baseline assessments, periodic follow-up visits to monitor safety and efficacy, and an end-of-study visit to collect final data and ensure participant well-being. The expected length of participant involvement will span the entire duration of the trial, from the initial screening to the end-of-study visit.

Conditions that may lead to early termination from the study include non-compliance with study procedures, adverse events that compromise participant safety, or withdrawal of consent. The study is conducted with no specific medical condition in focus, as it involves healthy volunteers. The trial's methodology and design are crafted to maintain scientific rigor and ensure the collection of high-quality data throughout the study period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial documentation lacks comprehensive information on the treatment protocols and participant management strategies.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on November 12, 2023, with an estimated completion date of March 21, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous clinical standards to evaluate the therapeutic impact of the investigational product, ensuring that all findings are scientifically valid and reliable.